论文部分内容阅读
目的观察丹红注射液联合曲美他嗪治疗不稳定型心绞痛疗效和安全性。方法64例不稳定型心绞痛患者随机分为对照组(32例)和观察组(32例)。对照组为常规治疗组,观察组在常规治疗组的基础上加用丹红注射液联合曲美他嗪。在治疗8周后分别对两组临床疗效、心电图及动态心电图变化进行对比分析,并观察患者的安全性及不良反应。结果丹红注射液联合曲美他嗪治疗组与对照组相比心绞痛控制有效率明显增加(P<0.05),心电图改善明显增加(P<0.05),动态心电图缺血发作次数、总缺血时间均显著减少(P<0.05),心率和收缩压乘积变化差异无显著性(P>0.05)。结论在常规治疗基础上加用丹红注射液联合曲美他嗪能更有效地控制不稳定心绞痛,且患者耐受性好,无不良反应。
Objective To observe the efficacy and safety of Danhong injection combined with trimetazidine in the treatment of unstable angina pectoris. Methods 64 patients with unstable angina were randomly divided into control group (32 cases) and observation group (32 cases). The control group was the conventional treatment group. The observation group was given Danhong injection combined with trimetazidine on the basis of the conventional treatment group. After 8 weeks of treatment, the clinical curative effect, electrocardiogram and electrocardiogram changes of the two groups were compared and analyzed, and the safety and adverse reactions of the patients were observed. Results Compared with the control group, the effective rate of angina pectoris in Danhong injection and trimetazidine treatment group was significantly increased (P <0.05), the improvement of electrocardiogram was significantly increased (P <0.05), the number of ischemic attacks of Holter monitoring, the total ischemic time (P <0.05). There was no significant difference in the product of heart rate and systolic pressure (P> 0.05). Conclusion Danhong injection combined with trimetazidine can be used to control unstable angina pectoris more effectively on the basis of routine treatment. The patients are well tolerated and have no adverse reactions.